Effects of Dietary Sodium and Protein Intake on Glomerular Filtration Rate in Subjects with Type 2 Diabetes Treated with Sodium-Glucose Cotransporter 2 Inhibitors

被引:0
|
作者
Gaudio, Costanza [1 ,2 ]
Seghieri, Marta [3 ,4 ]
Merciai, Chiara [1 ]
Colombi, Claudia [3 ]
Spatoliatore, Giuseppe [1 ]
Baggiore, Cristiana Maria [3 ]
Rosati, Alberto [1 ]
机构
[1] Nuovo San Giovanni Dio Hosp, Nephrol Unit, Florence, Italy
[2] Univ Florence, Dept Biomed Expt & Clin Sci Mario Serio, Florence, Italy
[3] Nuovo San Giovanni Dio Hosp, Diabet Unit, Florence, Italy
[4] Nuovo Osped San Giovanni Dio, Via Torregalli 1, I-50143 Florence, Italy
关键词
SGLT2; inhibitors; estimated GFR; creatinine clearance; salt intake; protein intake; KIDNEY; EMPAGLIFLOZIN; DAPAGLIFLOZIN; DECREASE; OUTCOMES;
D O I
10.1055/a-2041-1516
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Approximately one-fourth of patients treated with sodium-glucose cotransporter 2 inhibitors (SGLT2i) experience an acute estimated glomerular filtration rate (eGFR) reduction of more than 10 % ("dippers"). High sodium and protein intake can increase intraglomerular pressure and predispose to a decline in renal function. We investigated whether measured creatinine clearance (CrCl) is a sensitive enough method to detect the initial dip of GFR and if dietary sodium and protein intake might influence the extent of the early change in GFR. Methods 28 subjects with type 2 diabetes (T2D) were enrolled. For sodium and urea determination, 24-h urinary samples were collected to estimate sodium and protein intake respectively before and 1, 3 and 6 months after SGLT2i initiation. Results Mean CrCl was 83.23 +/- 25.52 mL/min/1.73 m(2) (eGFR 67.32 +/- 16.07) and dropped by 19 % at month 1 (eGFR by 6 %). Dippers were 64 and 40 %, according to CrCl and eGFR, respectively. Exploring the potential correlation between changes in renal function and salt intake,.CrCl and baseline urinary sodium were inversely related at month 1 (r = -0,61; p < 0.01), at month 3 (r = -0.51; p = 0.01) and month 6 (r = -0,48; p < 0.05). Likewise, an inverse correlation between.CrCl and baseline urinary urea was demonstrated at months 1 and 3 (r = -0.46; p < 0.05 for both); at month 6, a similar trend was observed (r = -0.47; p = 0.054). Conclusions The present study suggests that a higher dietary sodium and protein intake may amplify the extent of the early dip in GFR, as detected with measured CrCl, in diabetic patients undergoing SGLT2i treatment.
引用
收藏
页码:254 / 259
页数:6
相关论文
共 50 条
  • [1] Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes
    Siamashvili, Maka
    Davis, Stephen N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (16) : 2181 - 2198
  • [2] The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes
    Steen, Oren
    Goldenberg, Ronald M.
    CANADIAN JOURNAL OF DIABETES, 2017, 41 (05) : 517 - 523
  • [3] Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes
    Woo, Vincent C.
    CANADIAN JOURNAL OF DIABETES, 2020, 44 (01) : 61 - 67
  • [4] A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors
    Chaurasia, Pallavi Prakash
    Dholariya, Sagar
    Kotadiya, Fenilkumar
    Bhavsar, Milav
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)
  • [5] Lipid effects of sodium-glucose cotransporter 2 inhibitors
    Lazarte, Julieta
    Kanagalingam, Tharsan
    Hegele, Robert A.
    CURRENT OPINION IN LIPIDOLOGY, 2021, 32 (03) : 183 - 190
  • [6] Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes
    Chilton, Robert J.
    DIABETES OBESITY & METABOLISM, 2020, 22 (01): : 16 - 29
  • [7] Bibliometric and visualized analysis of sodium-Glucose cotransporter 2 inhibitors
    Sun, He
    Wang, Zhongqing
    Wang, Yuxi
    Rong, Haichuan
    Wang, Danyang
    Liu, Xiangnian
    Jin, Ke
    Sun, Zhicheng
    Fan, Qiuling
    FRONTIERS IN PHARMACOLOGY, 2023, 13
  • [8] Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias
    Manolis, Antonis A.
    Manolis, Theodora A.
    Melita, Helen
    Manolis, Antonis S.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2023, 33 (07) : 418 - 428
  • [9] Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes
    Trujillo, Jennifer M.
    Nuffer, Wesley A.
    PHARMACOTHERAPY, 2017, 37 (04): : 481 - 491
  • [10] Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
    Kim, Yoojin
    Babu, Ambika R.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2012, 5 : 313 - 327